| EMERGENT BIOSOLUTIONS |
| USA |
| Gesundheit |
| US29089Q1058 / A0LC2W |
| ER4 (Frankfurt) / EBS (NYSE) |
| FRA:ER4, ETR:ER4, ER4:GR, NYSE:EBS |
| - |
| https://www.emergentbioso.. |
|
Emergent BioSolutions Inc. is a global life sciences company that primarily focuses on the development, manufacturing, and distribution of a wide array of medical products. These products are designed to address public health threats including chemic..
>Volltext.. |
| 375.77 Mio. EUR |
| 786.07 Mio. EUR |
| 583.32 Mio. EUR |
| 143.59 Mio. EUR |
| -7.41 Mio. EUR |
| -0.15 EUR |
| 547.29 Mio. EUR |
| 139.19 Mio. EUR |
| - |
| 1.09 |
| -34.36% |
| 93.88% |
| - |
| - |
| - |
| EMERGENT BIOSOLUTIONS, EMERGENT BIO |
| 26.05.26 |
|
||||
|
||||
|
||||
|
||||
|